The report contains a Japanese receipt-score-based estimate of 0.91 million JPY per month for tirabrutinib treatment. This is a treatment-cost estimate, not a United States average sales price, wholesale acquisition cost, or estimate of the change in a payer's total budget following tirabrutinib adoption.
No tirabrutinib-specific budget impact model was identified in the evidence assembled for this report. The available treatment-cost evidence does not establish population-level budget impact, offsets from avoided healthcare utilization, or cost-effectiveness.